UPDATED May 18, 2024
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
GTHX | US$4.53 | -5.0% | 58.4% | US$236.8m | US$8.50 | PS2.8x | E48.3% | n/a | Pharmaceuticals & Biotech | ||
HHR | AU$0.007 | 0% | -72.0% | AU$19.7m | n/a | PE6.7x | E86.3% | n/a | Energy | ||
CRNA | kr2.25 | -3.4% | -87.0% | kr18.7m | kr12.00 | PS151.7x | E92.9% | n/a | Pharmaceuticals & Biotech | ||
ACTD | US$7.79 | -24.2% | -21.2% | US$303.0m | US$17.00 | PE-25.3x | E85.2% | n/a | Diversified Financials | ||
CDX | AU$0.055 | 14.6% | -76.6% | AU$16.2m | n/a | PS1.1x | E114.3% | n/a | Healthcare | ||
MTVFR | €0.018 | 3.5% | 17.1% | €3.5m | n/a | PS1x | E58.5% | 0% | Media | ||
XBRANE | kr0.20 | -12.0% | -99.8% | kr309.0m | n/a | PS1.6x | E105.2% | n/a | Pharmaceuticals & Biotech | ||
2GI | €2.70 | -10.0% | n/a | €11.3m | n/a | PB0.2x | E76.2% | 0% | Real Estate Management and Development | ||
ALACT | €0.96 | 19.7% | -84.3% | €12.6m | €1.00 | PB34.3x | E81.5% | n/a | Pharmaceuticals & Biotech | ||
ZWIPE | kr0.64 | 8.5% | -85.0% | kr63.6m | kr2.00 | PS30.3x | E73.3% | n/a | Tech | ||
ASTS | US$4.54 | 100.9% | -14.0% | US$1.2b | US$13.28 | PS1267.8x | E70.6% | n/a | Telecom | ||
ACR | AU$0.063 | -1.6% | 26.0% | AU$18.3m | n/a | PS1.6x | E115.3% | 0% | Pharmaceuticals & Biotech | ||
ALPHE | €2.00 | 2.6% | -53.6% | €14.4m | €5.80 | PS4.6x | E78.8% | n/a | Pharmaceuticals & Biotech | ||
CLBIO | kr10.50 | 4.0% | -35.0% | kr225.7m | kr29.00 | PS7.3x | E114.8% | n/a | Pharmaceuticals & Biotech | ||
SAR | UK£0.34 | 17.2% | -72.8% | UK£36.7m | UK£1.76 | PB88x | E117.2% | n/a | Pharmaceuticals & Biotech | ||
PBH | AU$0.46 | 0% | -70.6% | AU$148.1m | n/a | PB1x | E116.8% | n/a | Consumer Services | ||
OCUP | US$1.69 | -2.0% | -61.2% | US$43.2m | US$19.33 | PS2.3x | E51.0% | n/a | Pharmaceuticals & Biotech | ||
1086 | HK$0.63 | -6.0% | 3.3% | HK$1.1b | n/a | PE5.2x | E21.8% | 0% | Consumer Durables | ||
CALTX | kr117.20 | 5.8% | 13.8% | kr6.3b | kr208.00 | PS5.2x | E49.9% | n/a | Pharmaceuticals & Biotech | ||
ZYNE | US$1.30 | 4.0% | 96.1% | US$65.6m | US$1.26 | PB2.3x | E67.2% | n/a | Pharmaceuticals & Biotech | ||
ZVRA | US$4.73 | -1.9% | -12.4% | US$198.0m | US$19.00 | PS7.1x | E65.3% | n/a | Pharmaceuticals & Biotech | ||
IVVD | US$2.40 | 6.2% | 93.5% | US$286.1m | US$9.23 | PB1.6x | E69.8% | n/a | Pharmaceuticals & Biotech | ||
MDP | CA$1.60 | 0.6% | 23.1% | CA$39.1m | CA$3.21 | PE4.9x | E46.9% | n/a | Pharmaceuticals & Biotech | ||
TIE | AU$0.67 | -2.2% | 22.0% | AU$762.4m | n/a | PE168.2x | E61.2% | n/a | Materials |